Hormonal
Daily supplementation with a combination of nicotinamide riboside (NR) and pterostilbene (NRPT) at the recommended dose significantly reduces circulating levels of hepatic inflammation markers (ALT and GGT) and toxic lipids (ceramide 14:0) in adults with Non-Alcoholic Fatty Liver Disease (NAFLD) over 6 months, without reducing hepatic fat fraction.
If you have NAFLD, a specific combination of Nicotinamide Riboside and Pterostilbene (taken daily at the recommended dose) may help lower liver inflammation markers (ALT, GGT) and toxic lipids over 6 months. However, do not expect this supplement to reduce the actual amount of fat in your liver, as the study showed no improvement in hepatic fat fraction compared to a placebo.
Among prespecified secondary outcomes, a time-dependent decrease in the circulating levels of the liver enzymes alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) was observed in the NRPT 1× group, and this decrease was significant with respect to placebo. Furthermore, a significant decrease in the circulating levels of the toxic lipid ceramide 14:0 was also observed in the NRPT 1× group versus placebo...
Why this rating
Double-blind, placebo-controlled randomized clinical trial (RCT) with 111 participants, though the primary endpoint was missed.
Source
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial
Ryan W. Dellinger et al. · Hepatology · 2022
DOI 10.1002/hep.32778
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →